» Articles » PMID: 35840697

Impairing Proliferation of Glioblastoma Multiforme with CD44+ selective Conjugated Polymer Nanoparticles

Abstract

Glioblastoma is one of the most aggressive types of cancer with success of therapy being hampered by the existence of treatment resistant populations of stem-like Tumour Initiating Cells (TICs) and poor blood-brain barrier drug penetration. Therapies capable of effectively targeting the TIC population are in high demand. Here, we synthesize spherical diketopyrrolopyrrole-based Conjugated Polymer Nanoparticles (CPNs) with an average diameter of 109 nm. CPNs were designed to include fluorescein-conjugated Hyaluronic Acid (HA), a ligand for the CD44 receptor present on one population of TICs. We demonstrate blood-brain barrier permeability of this system and concentration and cell cycle phase-dependent selective uptake of HA-CPNs in CD44 positive GBM-patient derived cultures. Interestingly, we found that uptake alone regulated the levels and signaling activity of the CD44 receptor, decreasing stemness, invasive properties and proliferation of the CD44-TIC populations in vitro and in a patient-derived xenograft zebrafish model. This work proposes a novel, CPN- based, and surface moiety-driven selective way of targeting of TIC populations in brain cancer.

Citing Articles

Utilisation of High Molecular Weight and Ultra-High Molecular Weight Hyaluronan in Management of Glioblastoma.

Salagean A, Moldovan C, Slevin M Gels. 2025; 11(1).

PMID: 39852021 PMC: 11764969. DOI: 10.3390/gels11010050.


Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment.

Gawel A, Betkowska A, Gajda E, Godlewska M, Gawel D Biomedicines. 2024; 12(8).

PMID: 39200286 PMC: 11351974. DOI: 10.3390/biomedicines12081822.


Human glioblastoma-derived cell membrane nanovesicles: a novel, cell-specific strategy for boron neutron capture therapy of brain tumors.

Balboni A, Ailuno G, Baldassari S, Drava G, Petretto A, Grinovero N Sci Rep. 2024; 14(1):19225.

PMID: 39160236 PMC: 11333626. DOI: 10.1038/s41598-024-69696-7.


NRBP1 promotes malignant phenotypes of glioblastoma by regulating PI3K/Akt activation.

Zhang A, Peng S, Sun S, Ye S, Zhao Y, Wu Q Cancer Med. 2024; 13(16):e70100.

PMID: 39149873 PMC: 11327863. DOI: 10.1002/cam4.70100.


Glioblastoma research on zebrafish xenograft models: a systematic review.

Pliakopanou A, Antonopoulos I, Darzenta N, Serifi I, Simos Y, Katsenos A Clin Transl Oncol. 2023; 26(2):311-325.

PMID: 37400666 PMC: 10810942. DOI: 10.1007/s12094-023-03258-7.


References
1.
Yang L, Song X, Gong T, Jiang K, Hou Y, Chen T . Development a hyaluronic acid ion-pairing liposomal nanoparticle for enhancing anti-glioma efficacy by modulating glioma microenvironment. Drug Deliv. 2018; 25(1):388-397. PMC: 6058578. DOI: 10.1080/10717544.2018.1431979. View

2.
Wolf K, Shukla P, Springer K, Lee S, Coombes J, Choy C . A mode of cell adhesion and migration facilitated by CD44-dependent microtentacles. Proc Natl Acad Sci U S A. 2020; 117(21):11432-11443. PMC: 7261014. DOI: 10.1073/pnas.1914294117. View

3.
Adamson C, Kanu O, Mehta A, Di C, Lin N, Mattox A . Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009; 18(8):1061-83. DOI: 10.1517/13543780903052764. View

4.
Wang D, Wang C, Wang L, Chen Y . A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment. Drug Deliv. 2020; 26(1):551-565. PMC: 6534214. DOI: 10.1080/10717544.2019.1616235. View

5.
Miletti-Gonzalez K, Murphy K, Kumaran M, Ravindranath A, Wernyj R, Kaur S . Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem. 2012; 287(23):18995-9007. PMC: 3365933. DOI: 10.1074/jbc.M111.318774. View